Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
← catalyst calendarNCT07517198 · readout ≤ 954 d
Sponsored by Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. (industry) · RXRX — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
40estimated
Sites
3
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-04-13 | actual | When the study began enrolling |
| Primary completion | Mar 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2026-04-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Solid Tumor
- Small Cell Lung Cancer (SCLC)
- High Grade Neuroendocrine Cancer
- Small Cell Carcinomas of Non-lung Origin
- Non-small Cell Lung Cancer (NSCLC)
- Prostate Cancer
- Ovarian Cancer
- Renal Carcinoma (Clear and Non-clear Cell)
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Hepatic Cancer
- Gastric Cancer
- Triple-negative Breast Cancer (TNBC)
Intervention
- Drug: EXS74539 — also filed as REC-4539
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
measured Up to 3 years
Number of Participants with Dose-limiting Toxicity (DLT)
measured Up to 28 days
Number of Participants with Dose Interruptions and Dose Modifications
measured Up to 3 years
Permalink · RXRX's whole pipeline · Catalyst calendar · Every registered study · What changed